Pfizers BRAFTOVI®-Kombinationsregime zeigt verbesserte Reaktion bei Patienten mit BRAF V600E-mutiertem metastasiertem Kolorektalkrebs
It works by blocking the activity of the mutated BRAF protein, which is commonly found in various types of cancer, including metastatic colorectal cancer. BRAFTOVI has been shown to be effective in combination with other treatments, such as cetuximab and mFOLFOX6, in patients with BRAF V600E-mutant mCRC. The results of the Phase 3 BREAKWATER trial … Weiterlesen